Please select the option that best describes you:
Topics:
Hematologic Malignancies • Medical Oncology • Bone Marrow Transplant • Lymphoma • Internal Medicine • Hematology
How do you approach front line treatment for TP53 mutated mantle cell lymphoma?
Since some prior studies (eg. Eskelund et al.
Answer from: Medical Oncologist at Academic Institution
For patients with TP53 mutations based on the information presented by Eskelund et al. and previous experience. Given the knowledge that the mutation is a dominant negative which eliminates and functional activity of the tumor suppressor it stands to reason that an durable response wi...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
Both R2 and I+R (or acala+R) are reasonable front-line approaches. Both approaches are tougher in those with proliferative bulky nodal disease (ki67>50%). We still can get responses, but is less common, and particularly for I+R, remissions tend to be shorter. If in this si...